Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Study to Compare Capsule and Liquid Formulations of Enzalutamide After Single Dose Administration Under Fasting Conditions in Prostate Cancer

Trial Profile

Study to Compare Capsule and Liquid Formulations of Enzalutamide After Single Dose Administration Under Fasting Conditions in Prostate Cancer

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 12 Dec 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Enzalutamide (Primary) ; Enzalutamide (Primary)
  • Indications Prostate cancer
  • Focus Pharmacokinetics
  • Most Recent Events

    • 10 Dec 2019 Planned initiation date (estimated date for recruitment of the first subject) changed from 2 Dec 2019 to 16 Dec 2019.
    • 26 Nov 2019 Planned initiation date (estimated date for recruitment of the first subject) changed from 29 Nov 2019 to 2 Dec 2019.
    • 23 Nov 2019 Planned initiation date (estimated date for recruitment of the first subject) changed from 1 Nov 2019 to 29 Nov 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top